Verve Therapeutics, Inc. (VERV)
USD 5.09
(-9.27%)
USD 5.09
(-9.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -149.54 Million | -122.33 Million | -77.88 Million | -35.26 Million | -7.44 Million |
| Net Income | -200.06 Million | -157.38 Million | -120.31 Million | -45.7 Million | -19.29 Million |
| Depreciation & Amortization | 5.45 Million | 2.8 Million | 1.53 Million | 1.32 Million | 106 Thousand |
| Deferred income taxes | -48 Million | - | 1.5 Million | 380 Thousand | -72 Thousand |
| Stock-based compensation | 35.11 Million | 22.47 Million | 7.07 Million | 850 Thousand | 446 Thousand |
| Change in working capital | 17.7 Million | 8.38 Million | -2.91 Million | 2.64 Million | 2.66 Million |
| Other non-cash items | 40.25 Million | 1.39 Million | 35.23 Million | 5.23 Million | 8.71 Million |
| Investing Cash Flow | 27.69 Million | -155.95 Million | -239.09 Million | -51.12 Million | -12.75 Million |
| Investments in PPE | -9.28 Million | -13.23 Million | -4.35 Million | -3.42 Million | -1.85 Million |
| Acquisitions | -36.97 Million | 142.72 Million | 234.73 Million | 47.7 Million | 10.9 Million |
| Investment purchases | -517.14 Million | -479.4 Million | -371.49 Million | -98.48 Million | -22 Million |
| Sales/Maturities of investments | 554.11 Million | 336.67 Million | 136.75 Million | 50.78 Million | 11.1 Million |
| Other Investing Activities | 36.97 Million | -142.72 Million | -234.73 Million | -47.7 Million | -10.9 Million |
| Financing Cash Flow | 212.57 Million | 328.95 Million | 377.08 Million | 92.62 Million | 17.95 Million |
| Debt repayment | - | - | - | - | -110 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 212.57 Million | 326.49 Million | 285.21 Million | 92.62 Million | 18.04 Million |
| Other Financing Activities | -458 Thousand | 2.46 Million | 91.87 Million | 92.62 Million | 24 Thousand |
| Accounts receivables | -5.89 Million | -1.01 Million | - | - | - |
| Accounts payables | 3.91 Million | -5.21 Million | 6.82 Million | -1.89 Million | 1.73 Million |
| Inventory | - | 1.01 Million | - | - | - |
| Other working capital | 19.68 Million | 13.59 Million | -9.74 Million | 4.54 Million | 926 Thousand |
| Cash at beginning of period | 115.41 Million | 69.56 Million | 9.45 Million | 3.22 Million | 5.46 Million |
| Cash at end of period | 206.18 Million | 120.23 Million | 69.56 Million | 9.45 Million | 3.22 Million |
| Capital Expenditure | -9.28 Million | -13.23 Million | -4.35 Million | -3.42 Million | -1.85 Million |
| Effect of forex changes on cash | 50 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 90.76 Million | 50.66 Million | 60.11 Million | 6.23 Million | -2.24 Million |
| Free Cash Flow | -158.83 Million | -135.56 Million | -82.23 Million | -38.68 Million | -9.29 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -50.13 Million | -49.8 Million | -48.73 Million | -48.35 Million | -200.06 Million | -45.75 Million |
| Depreciation & Amortization | 1.75 Million | 1.66 Million | 1.63 Million | 1.51 Million | 5.45 Million | 1.47 Million |
| Deferred income taxes | - | - | - | -10.56 Million | -48 Million | -3.49 Million |
| Stock-based compensation | 10.81 Million | 11.64 Million | 10.34 Million | 9.25 Million | 35.11 Million | 8.82 Million |
| Change in working capital | -1.7 Million | 5.75 Million | -4.04 Million | -2.22 Million | 17.7 Million | 26.21 Million |
| Other non-cash items | -337 Thousand | 5.32 Million | 14.46 Million | 9.68 Million | 40.25 Million | 923 Thousand |
| Investing Cash Flow | 56.81 Million | 30.15 Million | -41.63 Million | -8.89 Million | 27.69 Million | -11.83 Million |
| Investments in PPE | -936 Thousand | -980 Thousand | -433 Thousand | -2.18 Million | -9.28 Million | -1.06 Million |
| Acquisitions | - | - | - | 6.7 Million | -36.97 Million | 10.77 Million |
| Investment purchases | -74.83 Million | -111.9 Million | -164.19 Million | -122.32 Million | -517.14 Million | -147.94 Million |
| Sales/Maturities of investments | 132.57 Million | 143.03 Million | 122.99 Million | 115.61 Million | 554.11 Million | 137.16 Million |
| Other Investing Activities | - | 31.13 Million | -41.19 Million | -6.7 Million | 36.97 Million | -10.77 Million |
| Financing Cash Flow | 14 Thousand | 1.29 Million | 22.73 Million | 177.38 Million | 212.57 Million | 31.92 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 472 Thousand | - | - | - | - | - |
| Common Stock Issuance | -1.59 Million | 1.29 Million | 22.73 Million | 177.38 Million | 212.57 Million | 31.77 Million |
| Other Financing Activities | 1.14 Million | 1.29 Million | -51 Thousand | -393 Thousand | -458 Thousand | 148 Thousand |
| Accounts receivables | -2.85 Million | 2.68 Million | 168 Thousand | -2.77 Million | -5.89 Million | - |
| Accounts payables | -2.56 Million | 3.55 Million | -3.3 Million | 4.49 Million | 3.91 Million | -2.06 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.39 Million | -487.99 Thousand | -904 Thousand | -3.94 Million | 19.68 Million | 28.27 Million |
| Cash at beginning of period | 141.49 Million | 144.2 Million | 206.18 Million | 78.37 Million | 115.41 Million | 74.86 Million |
| Cash at end of period | 163.48 Million | 141.49 Million | 144.2 Million | 206.18 Million | 206.18 Million | 83.14 Million |
| Capital Expenditure | -936 Thousand | -980 Thousand | -433 Thousand | -2.18 Million | -9.28 Million | -1.06 Million |
| Effect of forex changes on cash | - | - | - | -15.09 Million | 50 Thousand | -3.17 Million |
| Net cash flow / Change in cash | 21.99 Million | -2.71 Million | -61.98 Million | 127.81 Million | 90.76 Million | 8.27 Million |
| Free Cash Flow | -40.54 Million | -35.13 Million | -43.51 Million | -42.86 Million | -158.83 Million | -12.87 Million |
5027
0379
5303
PURPLE
MAXX
DNDPF